Is quantitative urinalysis more sensitive?

Outcome measures for assessing clinical efficacy of cocaine addiction pharmacotherapy should reliably and accurately reflect the benefits of the treatment. A core battery of outcome measures has been proposed by the Food and Drug Administration (FDA) and used by investigators for such trials. These measures include: (1) cocaine use by urinalysis, self-report, or both; (2) retention in treatment; (3) patient self-assessment; and (4) physician global assessment. Currently, urinalysis is the only generally accepted surrogate biological marker for objectively monitoring cocaine intake.